115 related articles for article (PubMed ID: 36356462)
1. Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer.
Kurokawa R; Kato S; Koyama H; Ishida M; Kurokawa M; Kuroda R; Ushiku T; Kume H; Abe O
Eur J Radiol; 2022 Dec; 157():110595. PubMed ID: 36356462
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. MR imaging features to predict the type of bone metastasis in prostate cancer.
Koyama H; Kurokawa R; Kato S; Ishida M; Kuroda R; Ushiku T; Kume H; Abe O
Sci Rep; 2023 Jul; 13(1):11580. PubMed ID: 37463944
[TBL] [Abstract][Full Text] [Related]
4. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
5. [
Janssen JC; Woythal N; Meißner S; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Mol Imaging Biol; 2017 Dec; 19(6):933-943. PubMed ID: 28707038
[TBL] [Abstract][Full Text] [Related]
6. Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.
Chen Y; Lin Y; Nie P; Jiang W; Liu Y; Yuan R; Li M; Zhao S; Lin H; Li P; Zhang J; Hu Z; Xu J; Zhu X
Med Sci Monit; 2017 Apr; 23():1768-1774. PubMed ID: 28400549
[TBL] [Abstract][Full Text] [Related]
7. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
[TBL] [Abstract][Full Text] [Related]
8. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
[TBL] [Abstract][Full Text] [Related]
9. Characterization of bone metastases detected on
Önner H; Yılmaz F
Hell J Nucl Med; 2022; 25(1):57-62. PubMed ID: 35503556
[TBL] [Abstract][Full Text] [Related]
10. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
11.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
13. Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
Lee SH; Chung MS; Park KK; Yom CD; Lee DH; Chung BH
World J Urol; 2012 Apr; 30(2):265-9. PubMed ID: 21779835
[TBL] [Abstract][Full Text] [Related]
14. MRI-based texture analysis of the primary tumor for pre-treatment prediction of bone metastases in prostate cancer.
Wang Y; Yu B; Zhong F; Guo Q; Li K; Hou Y; Lin N
Magn Reson Imaging; 2019 Jul; 60():76-84. PubMed ID: 30917943
[TBL] [Abstract][Full Text] [Related]
15. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.
Leisser A; Pruscha K; Ubl P; Wadsak W; Mayerhöfer M; Mitterhauser M; Hacker M; Kramer G; Shariat S; Karanikas G; Hartenbach M; Haug AR
Prostate; 2015 Nov; 75(15):1760-7. PubMed ID: 26282590
[TBL] [Abstract][Full Text] [Related]
17. Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans?
Sanjaya IP; Mochtar CA; Umbas R
Asian Pac J Cancer Prev; 2013; 14(9):4973-6. PubMed ID: 24175761
[TBL] [Abstract][Full Text] [Related]
18. Staging
Kesler M; Kerzhner K; Druckmann I; Kuten J; Levine C; Sarid D; Keizman D; Yossepowitch O; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2077-2085. PubMed ID: 34957528
[TBL] [Abstract][Full Text] [Related]
19. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of
Zhang Y; Lin Z; Li T; Wei Y; Yu M; Ye L; Cai Y; Yang S; Zhang Y; Shi Y; Chen W
Sci Rep; 2022 Sep; 12(1):15993. PubMed ID: 36163353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
